Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide.

ABSTRACT: Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in managing the disease, but they cannot reverse the pathology of the disease. Additionally, their parenteral administration is often associated with high healthcare costs, risk of infections, and poor patient adherence associated with phobia of needles. Oral delivery of these compounds would significantly improve patient compliance; however, poor enzymatic stability and low permeability across the gastrointestinal tract makes this task challenging. In the present work, large pore dendritic silica nanoparticles (DSNPs) with a pore size of ~10 nm w

SUBMITTER: Abeer MM 

PROVIDER: S-EPMC6723263 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature